IN2012DN00907A - - Google Patents
Info
- Publication number
- IN2012DN00907A IN2012DN00907A IN907DEN2012A IN2012DN00907A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A IN 907DEN2012 A IN907DEN2012 A IN 907DEN2012A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A
- Authority
- IN
- India
- Prior art keywords
- protein
- adamts13
- methods
- sample
- cation exchange
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 5
- 102000043853 ADAMTS13 Human genes 0.000 abstract 3
- 108091005670 ADAMTS13 Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 2
- 101800000620 Disintegrin-like Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102000002938 Thrombospondin Human genes 0.000 abstract 1
- 108060008245 Thrombospondin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 238000005571 anion exchange chromatography Methods 0.000 abstract 1
- 238000005341 cation exchange Methods 0.000 abstract 1
- 238000005277 cation exchange chromatography Methods 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000000415 inactivating effect Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Sustainable Development (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Water Supply & Treatment (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23030809P | 2009-07-31 | 2009-07-31 | |
| PCT/EP2010/061192 WO2011012726A2 (en) | 2009-07-31 | 2010-08-02 | Method for purifying recombinant adamts13 and other proteins and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00907A true IN2012DN00907A (es) | 2015-04-03 |
Family
ID=42588355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN907DEN2012 IN2012DN00907A (es) | 2009-07-31 | 2010-08-02 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8945895B2 (es) |
| EP (3) | EP4299735A3 (es) |
| JP (6) | JP5907869B2 (es) |
| KR (7) | KR101883610B1 (es) |
| CN (3) | CN107988192A (es) |
| AU (1) | AU2010277491B2 (es) |
| BR (1) | BR112012002140A2 (es) |
| CA (2) | CA2769362A1 (es) |
| CO (1) | CO6612194A2 (es) |
| DK (1) | DK2459715T3 (es) |
| EA (3) | EA201992487A1 (es) |
| ES (1) | ES2763207T3 (es) |
| HR (1) | HRP20192303T1 (es) |
| HU (1) | HUE046909T2 (es) |
| IN (1) | IN2012DN00907A (es) |
| LT (1) | LT2459715T (es) |
| MX (2) | MX2012001263A (es) |
| NZ (2) | NZ597756A (es) |
| PL (1) | PL2459715T3 (es) |
| PT (1) | PT2459715T (es) |
| SG (2) | SG178175A1 (es) |
| SI (1) | SI2459715T1 (es) |
| WO (1) | WO2011012726A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150098681A (ko) | 2007-03-14 | 2015-08-28 | 다케다 백신즈 인코포레이티드 | 바이러스 유사 입자 정제 |
| FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
| US20120238727A1 (en) * | 2011-03-14 | 2012-09-20 | Catalent Pharma Solutions Llc | Decorin compositions and use thereof |
| WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| WO2013028330A2 (en) * | 2011-08-19 | 2013-02-28 | Emd Millipore Corporation | Methods of reducing level of one of more impurities in a sample during protein purification |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| IN2014DN10441A (es) * | 2012-06-21 | 2015-08-21 | Baxter Int | |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| WO2014110246A1 (en) * | 2013-01-09 | 2014-07-17 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase a |
| EP2830651A4 (en) | 2013-03-12 | 2015-09-02 | Abbvie Inc | HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US8859252B1 (en) | 2014-01-02 | 2014-10-14 | Aerial Biopharma, Llc | Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same |
| AU2015214245B2 (en) * | 2014-02-04 | 2020-09-10 | Biogen Ma Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| MX2019001255A (es) | 2016-08-04 | 2019-05-20 | Baxalta Inc | Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda. |
| KR20200138346A (ko) * | 2018-04-03 | 2020-12-09 | 메르크 파텐트 게엠베하 | Cex 크로마토그래피 매질 및 생물제약 공급물로부터의 표적 단백질의 저염 용출 |
| KR102140531B1 (ko) * | 2018-08-07 | 2020-08-04 | (주)휴온스 | Gly-Tβ4의 제조방법 |
| EP3947705A1 (en) * | 2019-04-03 | 2022-02-09 | Genzyme Corporation | Continuous production of recombinant proteins |
| US11821000B2 (en) * | 2020-11-10 | 2023-11-21 | Dionex Corporation | Method of separating viral vectors |
| WO2023052556A1 (en) * | 2021-09-30 | 2023-04-06 | Ichnos Sciences SA | Methods of inactivating viral contaminants with a mixture of solvent and detergent |
| AU2023230335A1 (en) | 2022-03-07 | 2024-08-29 | Takeda Pharmaceutical Company Limited | Affinity chromatographic production of clinical human igg products |
| TW202400238A (zh) * | 2022-05-10 | 2024-01-01 | 南韓商綠十字股份有限公司 | 血漿蛋白之新穎液體調配物 |
| TW202400224A (zh) * | 2022-05-10 | 2024-01-01 | 南韓商綠十字股份有限公司 | 用於冷凍乾燥血漿蛋白之新穎液體調配物 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239854A (en) * | 1978-04-24 | 1980-12-16 | Sumitomo Chemical Company, Limited | Enzyme-immobilization carriers and preparation thereof |
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US5283182A (en) * | 1986-09-17 | 1994-02-01 | Beecham Group Plc | Preparation of immobilized hydantoinase stabilized with divalent metal ions |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| FR2681867B1 (fr) | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | Procede de purification du facteur viii et preparations obtenues. |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| JP4260877B2 (ja) | 1992-03-02 | 2009-04-30 | バイオエング・インコーポレーテッド | ウイルスの不活性化方法 |
| US5296228A (en) * | 1992-03-13 | 1994-03-22 | Allergan, Inc. | Compositions for controlled delivery of pharmaceutical compounds |
| US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
| US5578480A (en) * | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
| GB9503750D0 (en) * | 1995-02-24 | 1995-04-12 | Common Services Agency | Thrombin preparation |
| US5688912A (en) | 1995-09-22 | 1997-11-18 | Bayer Corporation | Peptide ligands which bind to von willebrand factor |
| US5831003A (en) | 1996-06-28 | 1998-11-03 | Bayer Corporation | Peptides which bind to prothrombin and thrombin |
| US5786458A (en) * | 1996-06-28 | 1998-07-28 | Bayer Corporation | Selective stabilization of protein during viral inactivation |
| US7141393B2 (en) * | 1996-12-26 | 2006-11-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Interleukin-18-receptor proteins |
| JP4707231B2 (ja) | 1998-06-10 | 2011-06-22 | スタテンズ セーラム インスティテュート | マンナン結合レクチンを製造するための精製方法及びｍｂｌ医薬品 |
| US6251860B1 (en) * | 1998-07-07 | 2001-06-26 | Suomen Punainen Risti Veripalvelu | Pharmaceutical preparations |
| US6214221B1 (en) | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
| US6451978B2 (en) * | 2000-01-21 | 2002-09-17 | Biovitrum Ab | Purification of antithrombin-III-α and β |
| IL136552A (en) | 2000-06-05 | 2005-05-17 | Omrix Biopharmaceuticals Ltd | Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration |
| AU2001294218A1 (en) * | 2000-10-11 | 2002-04-22 | Kazusa Dna Research Institute Foundation | Novel adamts family polypeptide and gene encoding the same |
| US6926894B2 (en) | 2000-11-22 | 2005-08-09 | Baxter Aktiengesellschaft | Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV |
| CN1230526C (zh) * | 2001-02-27 | 2005-12-07 | 成都夸常科技有限公司 | 一种除去作为病毒灭活剂的有机溶剂和/或去污剂的方法 |
| WO2003016492A2 (en) | 2001-08-16 | 2003-02-27 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
| JP2003144154A (ja) * | 2001-11-14 | 2003-05-20 | Mitsubishi Pharma Corp | 新規なａｄａｍｔｓファミリーポリペプチドおよびそれをコードする遺伝子 |
| EP1470160A2 (en) * | 2001-12-05 | 2004-10-27 | Cangene Corporation | Immune globulin formulations for the treatment and prevention of an orthopoxvirus infection |
| US20030133829A1 (en) * | 2001-12-21 | 2003-07-17 | Baxter Healthcare Corporation | Process for inactivating pathogens in a biological material |
| EP1463942B2 (en) | 2001-12-21 | 2012-06-20 | Immunex Corporation | Methods for purifying protein |
| GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| GB0216002D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
| WO2004035778A1 (ja) * | 2002-10-18 | 2004-04-29 | Japan As Represented By The President Of National Cardiovascular Center | フォンビルブランド因子切断酵素の特異的基質および活性測定法 |
| CA2487673C (en) * | 2003-12-02 | 2010-11-02 | F. Hoffmann-La Roche Ag | Improved method for the recombinant production and purification of protein kinases |
| GB0405330D0 (en) * | 2004-03-10 | 2004-04-21 | Astrazeneca Ab | Enzyme and preparation method |
| EP1740285A4 (en) * | 2004-04-13 | 2007-07-04 | Sangart Inc | METHOD AND COMPOSITIONS FOR SIMULTANEOUS ISOLATION OF HEMOGLOBIN FROM RED BLOOD BODIES AND INACTIVATION OF VIRUSES |
| ES2454566T3 (es) | 2004-06-07 | 2014-04-10 | Therapure Biopharma Inc. | Aislamiento de proteínas de plasma o suero |
| US7270976B2 (en) * | 2004-07-19 | 2007-09-18 | American Diagnostica, Inc. | Methods for measuring ADAMTS13 activity and protein on platelets and in plasma |
| DE102004044419B4 (de) * | 2004-09-14 | 2010-04-15 | Biotest Ag | Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie |
| US20090215699A1 (en) * | 2005-01-05 | 2009-08-27 | Foundation For Fatel Rare Diseases | Pharmaceutically Active Antiviral Peptides |
| US20060193966A1 (en) * | 2005-02-28 | 2006-08-31 | Shaowen Wu | Multi-anion treated soy proteins and methods for preparation thereof |
| ES2382104T3 (es) | 2005-06-17 | 2012-06-05 | Baxter International Inc. | Composiciones con actividad trombolítica que comprenden ADAMTS13 |
| FR2887883B1 (fr) | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| JP2009518345A (ja) * | 2005-12-07 | 2009-05-07 | テフニーシェ ウニヴェルジテート ミュンヘン | 因子ｖｉｉｉおよび因子ｖｉｉｉ様タンパク質に対する小型ペプチドおよびペプチド模倣物の親和性リガンド |
| JP5067917B2 (ja) | 2005-12-28 | 2012-11-07 | アルフレッサファーマ株式会社 | Ａｄａｍｔｓ１３の分離精製方法 |
| CN101384728B (zh) | 2006-02-16 | 2013-05-22 | 三菱化学美迪恩斯株式会社 | 意识障碍患者的病态检测方法和检测试剂盒 |
| US7468258B2 (en) | 2006-03-07 | 2008-12-23 | Wake Forest University Health Sciences | Self-quenching homofluorophore compositions for detecting enzyme activity |
| WO2008057074A1 (en) * | 2006-11-06 | 2008-05-15 | Millipore Corporation | Method of flow-through chromatography |
| US8669045B2 (en) | 2007-02-13 | 2014-03-11 | Ajinomoto Co., Inc. | Method for inactivating viruses with slightly acidic arginine |
| JP5254973B2 (ja) | 2007-06-22 | 2013-08-07 | 一般財団法人化学及血清療法研究所 | 新規ａｄａｍｔｓ−１３改変体 |
| FR2918375B1 (fr) * | 2007-07-05 | 2009-10-16 | Lab Francais Du Fractionnement | Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma |
| US8399620B2 (en) | 2007-07-11 | 2013-03-19 | Novo Nordisk A/S | Purification of factor VIII using a mixed-mode or multimodal resin |
| EP2197421A1 (en) * | 2007-08-31 | 2010-06-23 | Amgen, Inc | Solid-state protein formulation |
| US20090130714A1 (en) * | 2007-09-24 | 2009-05-21 | Reliance Life Sciences Pvt.Ltd. | Process for purifying recombinanat tissue plasminogen activator (TPA) |
-
2010
- 2010-07-30 US US12/847,956 patent/US8945895B2/en active Active
- 2010-08-02 KR KR1020177022447A patent/KR101883610B1/ko active IP Right Grant
- 2010-08-02 CN CN201711191958.3A patent/CN107988192A/zh active Pending
- 2010-08-02 AU AU2010277491A patent/AU2010277491B2/en active Active
- 2010-08-02 BR BR112012002140A patent/BR112012002140A2/pt not_active Application Discontinuation
- 2010-08-02 KR KR1020207036716A patent/KR20200146042A/ko not_active IP Right Cessation
- 2010-08-02 EP EP23210110.5A patent/EP4299735A3/en active Pending
- 2010-08-02 PT PT107379174T patent/PT2459715T/pt unknown
- 2010-08-02 EP EP17155619.4A patent/EP3211077B1/en active Active
- 2010-08-02 HU HUE10737917A patent/HUE046909T2/hu unknown
- 2010-08-02 MX MX2012001263A patent/MX2012001263A/es active IP Right Grant
- 2010-08-02 NZ NZ597756A patent/NZ597756A/en unknown
- 2010-08-02 CN CN201710433159.6A patent/CN107267490A/zh active Pending
- 2010-08-02 CA CA2769362A patent/CA2769362A1/en not_active Abandoned
- 2010-08-02 KR KR1020227016072A patent/KR20220066435A/ko not_active IP Right Cessation
- 2010-08-02 KR KR1020237042089A patent/KR20230170815A/ko not_active Application Discontinuation
- 2010-08-02 CA CA2916508A patent/CA2916508A1/en not_active Abandoned
- 2010-08-02 WO PCT/EP2010/061192 patent/WO2011012726A2/en active Application Filing
- 2010-08-02 KR KR1020127004995A patent/KR101769634B1/ko active IP Right Grant
- 2010-08-02 IN IN907DEN2012 patent/IN2012DN00907A/en unknown
- 2010-08-02 SG SG2012006581A patent/SG178175A1/en unknown
- 2010-08-02 MX MX2014008412A patent/MX348178B/es unknown
- 2010-08-02 KR KR1020197031048A patent/KR20190122272A/ko active Application Filing
- 2010-08-02 SG SG2013066824A patent/SG193855A1/en unknown
- 2010-08-02 KR KR1020187021317A patent/KR20180087463A/ko active Application Filing
- 2010-08-02 SI SI201031958T patent/SI2459715T1/sl unknown
- 2010-08-02 LT LTEP10737917.4T patent/LT2459715T/lt unknown
- 2010-08-02 DK DK10737917.4T patent/DK2459715T3/da active
- 2010-08-02 EA EA201992487A patent/EA201992487A1/ru unknown
- 2010-08-02 ES ES10737917T patent/ES2763207T3/es active Active
- 2010-08-02 PL PL10737917T patent/PL2459715T3/pl unknown
- 2010-08-02 EA EA201500952A patent/EA034292B1/ru not_active IP Right Cessation
- 2010-08-02 JP JP2012522191A patent/JP5907869B2/ja active Active
- 2010-08-02 EA EA201270214A patent/EA023783B1/ru not_active IP Right Cessation
- 2010-08-02 EP EP10737917.4A patent/EP2459715B1/en active Active
- 2010-08-02 NZ NZ620988A patent/NZ620988A/en unknown
- 2010-08-02 CN CN2010800370780A patent/CN102482660A/zh active Pending
-
2012
- 2012-02-14 CO CO12025851A patent/CO6612194A2/es unknown
-
2014
- 2014-12-16 US US14/571,670 patent/US11661593B2/en active Active
-
2015
- 2015-05-25 JP JP2015105808A patent/JP6216930B2/ja active Active
-
2016
- 2016-09-30 JP JP2016194640A patent/JP2016222724A/ja not_active Withdrawn
-
2018
- 2018-10-03 JP JP2018188301A patent/JP2018203781A/ja not_active Withdrawn
-
2019
- 2019-12-20 HR HRP20192303TT patent/HRP20192303T1/hr unknown
-
2020
- 2020-10-16 JP JP2020174837A patent/JP2021004265A/ja active Pending
-
2022
- 2022-09-21 JP JP2022150048A patent/JP2022171925A/ja active Pending
-
2023
- 2023-04-11 US US18/298,742 patent/US20230242897A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00907A (es) | ||
| MX2018014395A (es) | Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a. | |
| MX341136B (es) | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar la cromatografia de afinidad con proteina a. | |
| CA2551345C (fr) | Procede de separation des proteines fibrinogenes, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines | |
| JP2013500711A5 (es) | ||
| MX2007003906A (es) | Metodos y composiciones para mejorar la produccion de proteinas recombinantes. | |
| PH12015502408A1 (en) | Purification of iduronate-2-sulfatase | |
| SG157346A1 (en) | Improved purification of collagenases from clostridium histolyticum liquid culture | |
| WO2010048192A3 (en) | Viral inactivation during purification of antibodies | |
| MX2011011454A (es) | Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas. | |
| WO2008085962A3 (en) | Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants | |
| DK0891420T3 (da) | Fremgangsmåde til replikation af influenzavirus i cellekultur samt de ved fremgangsmåden opnåelige influenzavirus | |
| MY174493A (en) | Binding agents | |
| MX2007013759A (es) | Agentes de union de esclerostina. | |
| WO2011097381A8 (en) | Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof | |
| WO2006091535A3 (en) | Novel egg receptors for sperm proteins | |
| BRPI1013956B8 (pt) | método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão | |
| MX2022001166A (es) | Metodo para inactivacion viral. | |
| EP1870454A4 (en) | PROCESS FOR DIPEPTIDE PRODUCTION | |
| ATE553194T1 (de) | Verfahren zur dipeptidherstellung | |
| Moriguchi et al. | Reduction of plant-specific arabinogalactan-type O-glycosylation by treating tobacco plants with ferrous chelator 2, 2′-dipyridyl | |
| AU2003277694A1 (en) | Porcine uroplakin ii promoter and the production method of useful proteins using said promoter | |
| WO2022133191A3 (en) | Protein compositions and methods for producing and using the same | |
| WO2007064829A3 (en) | Novel purified polypeptides involved in bacterial fatty acid biosynthesis |